355 related articles for article (PubMed ID: 28696828)
1. Small molecule inhibitor TW-37 is tolerable and synergistic with chemotherapy in nasopharyngeal carcinoma.
Lu Y; Huang H; Yang H; Chen D; Wu S; Jiang Z; Wang R
Cell Cycle; 2017 Jul; 16(14):1376-1383. PubMed ID: 28696828
[TBL] [Abstract][Full Text] [Related]
2. ABT-199-mediated inhibition of Bcl-2 as a potential therapeutic strategy for nasopharyngeal carcinoma.
Wang Y; Wang Y; Fan X; Song J; Wu H; Han J; Lu L; Weng X; Nie G
Biochem Biophys Res Commun; 2018 Sep; 503(3):1214-1220. PubMed ID: 30017199
[TBL] [Abstract][Full Text] [Related]
3. The small molecule Bcl-2/Mcl-1 inhibitor TW-37 shows single-agent cytotoxicity in neuroblastoma cell lines.
Klenke S; Akdeli N; Stelmach P; Heukamp L; Schulte JH; Bachmann HS
BMC Cancer; 2019 Mar; 19(1):243. PubMed ID: 30885150
[TBL] [Abstract][Full Text] [Related]
4. XIAP Limits Autophagic Degradation of Sox2 and Is A Therapeutic Target in Nasopharyngeal Carcinoma Stem Cells.
Ji J; Yu Y; Li ZL; Chen MY; Deng R; Huang X; Wang GF; Zhang MX; Yang Q; Ravichandran S; Feng GK; Xu XL; Yang CL; Qiu MZ; Jiao L; Yang D; Zhu XF
Theranostics; 2018; 8(6):1494-1510. PubMed ID: 29556337
[No Abstract] [Full Text] [Related]
5. A novel Smac mimetic APG-1387 demonstrates potent antitumor activity in nasopharyngeal carcinoma cells by inducing apoptosis.
Li N; Feng L; Han HQ; Yuan J; Qi XK; Lian YF; Kuang BH; Zhang YC; Deng CC; Zhang HJ; Yao YY; Xu M; He GP; Zhao BC; Gao L; Feng QS; Chen LZ; Yang L; Yang D; Zeng YX
Cancer Lett; 2016 Oct; 381(1):14-22. PubMed ID: 27424523
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine and APG-1252, a novel small molecule inhibitor of BCL-2/BCL-XL, display a synergistic antitumor effect in nasopharyngeal carcinoma through the JAK-2/STAT3/MCL-1 signaling pathway.
Luo F; Lu FT; Qiu MZ; Zhou T; Ma WJ; Luo M; Zeng KM; Luo QY; Pan WT; Zhang L; Xia ZF; Zhang ZH; Cao JX; Zhao HY; Zhang L; Yang DJ
Cell Death Dis; 2021 Aug; 12(8):772. PubMed ID: 34354046
[TBL] [Abstract][Full Text] [Related]
7. TW-37, a small-molecule inhibitor of Bcl-2, mediates S-phase cell cycle arrest and suppresses head and neck tumor angiogenesis.
Ashimori N; Zeitlin BD; Zhang Z; Warner K; Turkienicz IM; Spalding AC; Teknos TN; Wang S; Nör JE
Mol Cancer Ther; 2009 Apr; 8(4):893-903. PubMed ID: 19372562
[TBL] [Abstract][Full Text] [Related]
8. Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1.
Mohammad RM; Goustin AS; Aboukameel A; Chen B; Banerjee S; Wang G; Nikolovska-Coleska Z; Wang S; Al-Katib A
Clin Cancer Res; 2007 Apr; 13(7):2226-35. PubMed ID: 17404107
[TBL] [Abstract][Full Text] [Related]
9. Morphine, a potential antagonist of cisplatin cytotoxicity, inhibits cisplatin-induced apoptosis and suppression of tumor growth in nasopharyngeal carcinoma xenografts.
Cao LH; Li HT; Lin WQ; Tan HY; Xie L; Zhong ZJ; Zhou JH
Sci Rep; 2016 Jan; 6():18706. PubMed ID: 26729257
[TBL] [Abstract][Full Text] [Related]
10. Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma.
Zhao Y; Zhang J; Tian Y; Xue C; Hu Z; Zhang L
Drug Des Devel Ther; 2015; 9():4897-907. PubMed ID: 26345996
[TBL] [Abstract][Full Text] [Related]
11. Suppression of BCL-2 synergizes cisplatin sensitivity in nasopharyngeal carcinoma cells.
Low SY; Tan BS; Choo HL; Tiong KH; Khoo AS; Leong CO
Cancer Lett; 2012 Jan; 314(2):166-75. PubMed ID: 22033244
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-29c enhances the sensitivities of human nasopharyngeal carcinoma to cisplatin-based chemotherapy and radiotherapy.
Zhang JX; Qian D; Wang FW; Liao DZ; Wei JH; Tong ZT; Fu J; Huang XX; Liao YJ; Deng HX; Zeng YX; Xie D; Mai SJ
Cancer Lett; 2013 Feb; 329(1):91-8. PubMed ID: 23142283
[TBL] [Abstract][Full Text] [Related]
13. TIMELESS confers cisplatin resistance in nasopharyngeal carcinoma by activating the Wnt/β-catenin signaling pathway and promoting the epithelial mesenchymal transition.
Liu SL; Lin HX; Lin CY; Sun XQ; Ye LP; Qiu F; Wen W; Hua X; Wu XQ; Li J; Song LB; Guo L
Cancer Lett; 2017 Aug; 402():117-130. PubMed ID: 28583847
[TBL] [Abstract][Full Text] [Related]
14. Promoting tumorigenesis in nasopharyngeal carcinoma, NEDD8 serves as a potential theranostic target.
Xie P; Yang JP; Cao Y; Peng LX; Zheng LS; Sun R; Meng DF; Wang MY; Mei Y; Qiang YY; Cao L; Xiang YQ; Luo DH; Yun JP; Huang BJ; Jia LJ; Qian CN
Cell Death Dis; 2017 Jun; 8(6):e2834. PubMed ID: 28569775
[TBL] [Abstract][Full Text] [Related]
15. Chemosensitizing Effect of Astragalus Polysaccharides on Nasopharyngeal Carcinoma Cells by Inducing Apoptosis and Modulating Expression of Bax/Bcl-2 Ratio and Caspases.
Zhou Z; Meng M; Ni H
Med Sci Monit; 2017 Jan; 23():462-469. PubMed ID: 28124680
[TBL] [Abstract][Full Text] [Related]
16. ApoG2, a novel inhibitor of antiapoptotic Bcl-2 family proteins, induces apoptosis and suppresses tumor growth in nasopharyngeal carcinoma xenografts.
Hu ZY; Zhu XF; Zhong ZD; Sun J; Wang J; Yang D; Zeng YX
Int J Cancer; 2008 Nov; 123(10):2418-29. PubMed ID: 18712728
[TBL] [Abstract][Full Text] [Related]
17. Tetrandrine Induces Apoptosis in Human Nasopharyngeal Carcinoma NPC-TW 039 Cells by Endoplasmic Reticulum Stress and Ca
Liu KC; Lin YJ; Hsiao YT; Lin ML; Yang JL; Huang YP; Chu YL; Chung JG
Anticancer Res; 2017 Nov; 37(11):6107-6118. PubMed ID: 29061791
[TBL] [Abstract][Full Text] [Related]
18. Resveratrol inhibits human nasopharyngeal carcinoma cell growth via blocking pAkt/p70S6K signaling pathways.
Zhang M; Zhou X; Zhou K
Int J Mol Med; 2013 Mar; 31(3):621-7. PubMed ID: 23314035
[TBL] [Abstract][Full Text] [Related]
19. LncRNA NEAT1/miR-129/Bcl-2 signaling axis contributes to HDAC inhibitor tolerance in nasopharyngeal cancer.
Xue F; Cheng Y; Xu L; Tian C; Jiao H; Wang R; Gao X
Aging (Albany NY); 2020 Jul; 12(14):14174-14188. PubMed ID: 32692721
[TBL] [Abstract][Full Text] [Related]
20. Exosomal ERp44 derived from ER-stressed cells strengthens cisplatin resistance of nasopharyngeal carcinoma.
Xia T; Tian H; Zhang K; Zhang S; Chen W; Shi S; You Y
BMC Cancer; 2021 Sep; 21(1):1003. PubMed ID: 34493236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
